Closeup photo of the hands of a senior woman grasping her walking cane

© Robert Kneschke – stock.adobe.com

News • Risk prediction

Kidney failure: frail CKD patients might fall under the radar

Researchers have found that a common tool used by clinicians for predicting kidney failure could be underestimating the risk of failure for some people.

The study – led by the University of Glasgow and published in the Clinical Journal of the American Society of Nephrology (CJASN) – suggests the Kidney Failure Risk Equation (KFRE), a prognostic tool that is widely recommended in clinical guidelines, could be underestimating the risk of kidney failure for individuals with chronic kidney disease who also have frailty. The findings – which looked at 24,489 people from the UK Biobank – also show that the prediction of kidney failure is improved for these people when a simple, alternative blood test, which can also be used to measure kidney function, is used alongside the KFRE tool. 

It is important not to overlook this group of patients, who are more likely to experience frailty alongside multiple long-term health conditions

Heather Walker,

The study shows that the addition of the cystatin C-test – with analyses accounting for the competing risk of people dying before they progress to kidney failure – could greatly improve predictions of kidney failure for this group of people. Cystatin C has been proposed as a more accurate test for assessing and estimating kidney function, compared to the commonly used creatinine test, particularly in older patients. Previous research has shown it can be a better way to test kidney function for some groups of people; and, as it is also more sensitive, may be able to identify a heightened risk of developing and dying from cancer in people with chronic kidney disease. 

Chronic kidney disease is characterised by gradual loss of kidney function over time,. Although kidney failure requiring dialysis is rare, mild kidney disease is common, affecting around 10% of the population, and it is usually asymptomatic and therefore not routinely diagnosed and monitored infrequently. 

Frailty – a condition of increased susceptibility and vulnerability to stressors, with increased risk of adverse events such as falls, delirium and hospitalisations – is also common amongst adults with chronic kidney disease, and its presence can impact chronic kidney disease and risk of death, and individuals with chronic kidney disease are more likely to experience frailty than those without it. 

Currently, clinical guidelines recommend the use of just the Kidney Failure Risk Equation (KFRE) to guide the management of the disease, and there is limited evidence to guide how chronic kidney disease management should be altered in the presence of frailty. 

Dr Heather Walker, Research Fellow at the University’s School of Cardiovascular and Metabolic Health, said: “Our findings could have important implications on clinical practice and the way patients with frailty and chronic kidney disease are tested and cared for. It is important not to overlook this group of patients, who are more likely to experience frailty alongside multiple long-term health conditions.”  

Dr Bhautesh Jani, Clinical Senior Lecturer at the University’s School of Health and Wellbeing, said: "Frailty is often related to ageing, and people with frailty are likely to have multiple health conditions. We need to improve our understanding of frailty's impact on health outcomes for conditions like chronic kidney disease to offer more appropriate treatment options for patients." 


Source: University of Glasgow 

12.08.2025

Related articles

Photo

News • Variation in attitudes to biopsy practice

Global gaps in diagnosing kidney disease revealed

When is a biopsy needed to diagnose a kidney disease? This is handled very differently around the world, a new study finds. This could result in adverse patient outcomes, the researchers warn.

Photo

News • Nuclear imaging marker

Renal cell carcinoma: New radiotracer improves detection and differentiation

A new PET tracer, 89Zr-DFO-girentuximab, can accurately detect a type of kidney cancer called clear cell renal cell carcinoma and differentiate it from other types of kidney tumors.

Photo

News • Algorithms put to the test

Diffusion MRI denoising: do sharper images equal better diagnostics?

Denoising of diffusion-weighted MRI data creates sharper images – but does it actually lead to better diagnostic results? Researchers explored the impact of noise removal on detecting abnormalities.

Related products

Subscribe to Newsletter